SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is generating strong community buzz as its AI-powered ecosystem expands with new exchange listings and cross-chain integrations, leading many to anticipate significant price milestones and further utility growth.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings is trending following a drastic stock plunge driven by the abrupt departure of its CFO and general counsel, an SEC investigation into cash management, and an accounting review exposing internal control weaknesses and revised future guidance, sparking intense community debate between those foreseeing catastrophe and others viewing it as an extreme overreaction and buying opportunity.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group is soaring after pre-announcing preliminary Q3 revenue well above expectations and reiterating robust fiscal year growth, fueling strong community belief that the AI data center infrastructure play was significantly undervalued amid massive hyperscaler capital expenditure. Traders are actively discussing the stock's sharp rebound and its potential for continued upside as a key beneficiary of the ongoing AI buildout.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

Rocket Companies Inc

Rocket Companies is seeing significant conversation after its CEO signaled multi-year highs in mortgage loan production and gain-on-sale performance, leading to community debate on whether its integrated platform can overcome broader housing market headwinds amidst ongoing institutional accumulation.

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

Satellos Bioscience Inc

MSLE is actively discussed following its recent NASDAQ listing, a reverse split, and a substantial equity raise. While optimists view the financing as a strong vote of confidence in its "revolutionary" muscle regeneration drug for Duchenne patients and foresee potential acquisition, skeptics caution about dilution and characterize early clinical data as premature hype.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is actively discussed as the community awaits crucial R2 SUV details and earnings, with its CEO emphasizing the R2's cost-efficient design and potential to significantly boost profitability, though investor sentiment remains divided on its market impact and the company's cash burn amid EV sector competition.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is a top trending stock as investors keenly await its earnings report tomorrow, with significant community speculation around a potential beat and strong guidance. Many perceive the cloud observability leader as an undervalued AI beneficiary after recent sector-wide pressures, driving discussions of a major buying opportunity.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is trending following the FDA's issuance of a Complete Response Letter for its Hunter syndrome gene therapy, RGX-121, citing concerns with trial design and the appropriateness of its surrogate endpoint. The community is actively debating the broader implications for gene therapies, RGNX's financial outlook, and potential impacts on its Duchenne and AbbVie-partnered programs.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is trending as its stock experiences a steep decline despite a recent Q4 earnings beat, prompting community concern over executive stock-based compensation and competitive pressures from rivals developing similar app features.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu is trending as its highly dedicated community champions a "permissionless brand" model, consistently launching real-world products like KENDU SPICE, fostering strong conviction and active accumulation even amidst broader market downturns. This unique approach to building real value differentiates it as a long-term play.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 4.5% - Time to Sell?

Aligos Therapeutics (NASDAQ:ALGS) Trading Down 4.5% - Here's What Happened...

Does Aligos Therapeutics (ALGS) Have the Potential to Rally 737.74% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 737.7% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia

SNY wins FDA approval for Wayrilz, the first BTK inhibitor for immune thrombocytopenia, with broader rare disease studies underway.

RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study

Rocket Pharmaceuticals' shares soar as the FDA lifts its clinical hold on the pivotal Danon disease gene therapy study.

Wall Street Analysts Predict a 983.24% Upside in Aligos Therapeutics (ALGS): Here's  What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 983.2% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus

ALLO posts a narrower second-quarter 2025 loss. The company advances multiple CAR T programs targeting cancer and autoimmune diseases.

Aligos Therapeutics, Inc. (ALGS) Reports Q2 Loss, Misses Revenue Estimates

Aligos Therapeutics (ALGS) delivered earnings and revenue surprises of +34.89% and -3.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 5, 2018 and is headquartered in South San Francisco, CA.

Aligos Therapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

ALGS
Aligos Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ALGS News

ALGSAligos Therapeutics Inc